Ferolla Silvia M, Couto Cláudia A, Costa-Silva Luciana, Armiliato Geyza N A, Pereira Cristiano A S, Martins Flaviano S, Ferrari Maria de Lourdes A, Vilela Eduardo G, Torres Henrique O G, Cunha Aloísio S, Ferrari Teresa C A
Departamento de ClínicaMédica, Faculdade de Medicina, Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte 30130-100, Brazil.
Departamento de Anatomia e Imagem, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte 30130-100, Brazil.
Nutrients. 2016 Jun 28;8(7):397. doi: 10.3390/nu8070397.
Nonalcoholic fatty liver disease is the most prevalent chronic liver disease in Western countries; it can progress to nonalcoholic steatohepatitis (NASH), cirrhosis and hepatocarcinoma. The importance of gut-liver-adipose tissue axis has become evident and treatments targeting gut microbiota may improve inflammatory and metabolic parameters in NASH patients. In a randomized, controlled clinical trial, involving 50 biopsy-proven NASH patients, we investigated the effects of synbiotic supplementation on metabolic parameters, hepatic steatosis, intestinal permeability, small intestinal bacterial overgrowth (SIBO) and lipopolysaccharide (LPS) serum levels. Patients were separated into two groups receiving Lactobacillus reuteri with guar gum and inulin for three months and healthy balanced nutritional counseling versus nutritional counseling alone. Before and after the intervention we assessed steatosis by magnetic resonance imaging, intestinal permeability by lactulose/mannitol urinary excretion and SIBO by glucose breath testing. NASH patients presented high gut permeability, but low prevalence of SIBO. After the intervention, only the synbiotic group presented a reduction in steatosis, lost weight, diminished BMI and waist circumference measurement. Synbiotic did not improve intestinal permeability or LPS levels. We concluded that synbiotic supplementation associated with nutritional counseling seems superior to nutritional counseling alone for NASH treatment as it attenuates steatosis and may help to achieve weight loss.
非酒精性脂肪性肝病是西方国家最常见的慢性肝病;它可进展为非酒精性脂肪性肝炎(NASH)、肝硬化和肝癌。肠-肝-脂肪组织轴的重要性已变得明显,针对肠道微生物群的治疗可能改善NASH患者的炎症和代谢参数。在一项纳入50例经活检证实的NASH患者的随机对照临床试验中,我们研究了补充合生元对代谢参数、肝脂肪变性、肠道通透性、小肠细菌过度生长(SIBO)和脂多糖(LPS)血清水平的影响。患者被分为两组,一组接受含有罗伊氏乳杆菌、瓜尔胶和菊粉的制剂三个月,并接受健康均衡营养咨询,另一组仅接受营养咨询。在干预前后,我们通过磁共振成像评估脂肪变性,通过乳果糖/甘露醇尿排泄评估肠道通透性,通过葡萄糖呼气试验评估SIBO。NASH患者肠道通透性高,但SIBO患病率低。干预后,只有合生元组的脂肪变性减轻、体重减轻、BMI和腰围测量值降低。合生元并未改善肠道通透性或LPS水平。我们得出结论,对于NASH治疗,补充合生元并结合营养咨询似乎优于单纯营养咨询,因为它可减轻脂肪变性并可能有助于实现体重减轻。